CVD Mortality Similar With Diuretic, ACE Inhibitor, or Calcium Channel Blocker
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 4, 2023 -- For patients with hypertension and at least one other coronary heart disease risk factor, cardiovascular disease (CVD) mortality is similar for those receiving a thiazide-type diuretic, calcium channel blocker (CCB), or angiotensin-converting enzyme (ACE) inhibitor, according to a study published online Dec. 4 in JAMA Network Open.
Jose-Miguel Yamal, Ph.D., from The University of Texas Health Science Center at Houston, and colleagues randomly assigned participants aged 55 years or older with a diagnosis of hypertension and at least one other coronary heart disease risk factor to receive a thiazide-type diuretic (15,002), a CCB (8,898), or an ACE inhibitor (8,904). Participants were followed for all-cause mortality due to CVD, and a subgroup of 22,754 participants were followed for fatal or nonfatal CVD.
The researchers found that CVD mortality rates were 23.7, 21.6, and 23.8 per 100 persons in the diuretic, CCB, and ACE inhibitor groups, respectively, at 23 years after randomization. For most secondary outcomes, the long-term risks were similar among the three groups. The ACE inhibitor group had increased risks for stroke mortality and for combined fatal and nonfatal hospitalized stroke compared with the diuretic group (adjusted hazard ratios, 1.19 and 1.11, respectively).
"Angiotensin-converting enzyme inhibitors were associated with an increased risk of stroke outcomes (11 percent increased risk of combined fatal and nonfatal hospitalized stroke) compared with diuretics, and this effect persisted well beyond the trial period," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Early Aortic Valve Intervention Not Beneficial for Severe Aortic Stenosis
THURSDAY, Oct. 31, 2024 -- For patients with asymptomatic severe aortic stenosis and myocardial fibrosis, early aortic valve intervention does not impact all-cause death or...
ASN: Hypertension Most Common Cardiovascular Comorbidity Seen With Dialysis
WEDNESDAY, Oct. 30, 2024 -- Hypertension is the most common cardiovascular disease (CVD) comorbidity seen among dialysis patients globally, according to a study presented at...
Knowledge of Abdominal Aortic Calcification Results Improves Some CVD Risk Factors
THURSDAY, Oct. 24, 2024 -- Providing vascular imaging results does not improve diet but does improve some cardiovascular disease risk factors at 12 weeks posttest, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.